| Quarterly Financials | Mar 2015 | Jun 2015 | Sept 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
Revenue  | 3,071 | 3,157 | 3,250 | 3,417 | 4,144 | 4,424 | 4,243 | 4,511 | 4,209 | 3,839 | 3,952 | 3,929 | 4,125 | 3,960 | 4,122 | 3,872 | 3,922 | 3,922 | 4,007 | 3,844 | 4,084 | 3,513 | 3,807 | 3,939 | 3,808 | 4,265 | 4,076 | 4,122 | 3,880 | 3,610 | 4,106 | 4,263 | 4,368 | 4,765 | 4,980 | 5,109 | 4,924 | 5,582 | 5,539 | 5,672 | 5,619 | 6,243 | 6,921 |
| Expenses | 2,289 | 2,331 | 2,667 | 2,702 | 2,883 | 3,157 | 3,260 | 3,264 | 3,472 | 3,104 | 3,099 | 3,287 | 4,789 | 3,329 | 3,401 | 3,608 | 3,107 | 3,131 | 3,788 | 3,629 | 3,320 | 3,040 | 3,254 | 3,239 | 3,066 | 3,306 | 5,415 | 3,791 | 3,615 | 3,512 | 3,693 | 3,790 | 3,852 | 3,958 | 4,121 | 4,160 | 3,964 | 4,359 | 4,332 | 4,412 | 4,346 | 4,541 | 4,706 |
| EBITDA | 783 | 825 | 583 | 715 | 1,261 | 1,268 | 983 | 1,246 | 737 | 735 | 853 | 642 | -665 | 631 | 721 | 264 | 814 | 791 | 219 | 215 | 763 | 473 | 553 | 700 | 742 | 960 | -1,339 | 331 | 265 | 98 | 414 | 473 | 515 | 807 | 859 | 950 | 960 | 1,223 | 1,207 | 1,261 | 1,273 | 1,702 | 2,215 |
| Operating Profit % | 25 % | 24 % | 16 % | 19 % | 30 % | 27 % | 23 % | 26 % | 17 % | 18 % | 20 % | 16 % | -20 % | 12 % | 13 % | 6 % | 18 % | 18 % | 1 % | 2 % | 12 % | 12 % | 14 % | 17 % | 18 % | 22 % | -35 % | 7 % | 6 % | 3 % | 10 % | 11 % | 11 % | 17 % | 17 % | 18 % | 19 % | 21 % | 21 % | 21 % | 22 % | 26 % | 31 % |
| Depreciation | 107 | 101 | 116 | 122 | 149 | 203 | 211 | 231 | 267 | 261 | 272 | 280 | 273 | 259 | 266 | 219 | 219 | 250 | 253 | 253 | 214 | 215 | 213 | 244 | 216 | 209 | 919 | 203 | 327 | 193 | 204 | 220 | 264 | 235 | 248 | 257 | 457 | 248 | 257 | 272 | 393 | 299 | 317 |
| Interest | 3 | 7 | 24 | 10 | 31 | 35 | 29 | 48 | 41 | 44 | 48 | 54 | 59 | 69 | 74 | 79 | 84 | 84 | 83 | 89 | 107 | 44 | 34 | 31 | 32 | 34 | 34 | 33 | 42 | 43 | 55 | 84 | 93 | 86 | 81 | 74 | 71 | 68 | 71 | 67 | 89 | 92 | 108 |
| Profit Before Tax | 697 | 792 | 581 | 781 | 1,170 | 1,156 | 822 | 1,045 | 520 | 494 | 611 | 383 | -941 | 384 | 441 | 93 | 591 | 518 | -54 | -73 | 496 | 273 | 360 | 525 | 518 | 751 | -2,205 | 167 | -85 | 2 | 210 | 246 | 259 | 559 | 630 | 736 | 498 | 993 | 1,055 | 1,071 | 896 | 1,416 | 2,007 |
| Tax | 136 | 224 | 158 | 255 | 417 | 273 | 159 | 410 | 137 | 137 | 154 | 161 | -163 | 181 | 173 | 245 | 294 | 216 | 70 | 767 | 105 | 164 | 147 | 84 | 54 | 202 | -110 | -382 | 427 | 89 | 75 | 89 | 16 | 106 | 134 | 117 | 130 | 188 | 195 | 212 | 114 | 194 | 522 |
| Net Profit | 561 | 568 | 422 | 526 | 753 | 883 | 663 | 636 | 384 | 357 | 457 | 222 | -778 | 203 | 269 | -152 | 296 | 303 | -123 | -840 | 391 | 109 | 214 | 441 | 464 | 548 | -2,095 | 549 | -512 | -87 | 135 | 158 | 242 | 453 | 495 | 619 | 368 | 806 | 860 | 859 | 782 | 1,222 | 1,485 |
| EPS in ₹ | 12.17 | 12.65 | 9.34 | 11.67 | 16.63 | 19.57 | 14.69 | 14.04 | 8.42 | 7.93 | 10.07 | 4.91 | -17.33 | 6.40 | 5.88 | -3.37 | 6.55 | 6.69 | -2.72 | -18.56 | 8.64 | 2.36 | 4.66 | 9.67 | 10.15 | 11.96 | -46.22 | 12.01 | -11.40 | -1.96 | 2.85 | 3.38 | 5.19 | 9.94 | 10.76 | 13.47 | 7.89 | 17.58 | 18.70 | 18.75 | 16.93 | 26.70 | 32.36 |
Lupin
Lupin
2,055.30
+2.40
(0.12%)
There are new updates from the company1 day ago
View
Key Fundamentals
Market Cap
93,876.80 Cr
EPS
71.95
PE Ratio
21.59
Dividend Yield
0.58 %
Industry
Healthcare 52 Week High
2,402.90
52 Week Low
1,795.20
PB Ratio
4.78
Debt to Equity
0.27
Sector
Pharmaceuticals Analyst Rating and Forecast
- By Refinitiv from36 analysts
Actual
Company News
View All News
Lupin confirmed that the FDA inspection of its Nagpur Unit-1 manufacturing facility has been closed with no issues identified. The successful inspection closure indicates the facility meets FDA regulatory standards, which is positive for the pharmaceutical company's operations and compliance status.
Lupin unveiled its Risperidone Long-Acting Injectable in the U.S. market, securing 180-day CGT exclusivity for the antipsychotic medication. This represents the first commercial launch from the company's PrecisionSphere platform technology, marking a significant milestone for Lupin's specialized drug delivery capabilities.
Lupin Limited announced it achieved an S&P Global ESG Score of 91 for 2025, significantly above the pharmaceutical industry average of 28. This places Lupin in an exclusive group of companies worldwide that have surpassed the 90-point mark. The score represents a dramatic increase from 17 in 2021 and a 15-point jump from the previous year. Ramesh Swaminathan, Executive Director and Global CFO, described achieving above 90 as a rare global distinction that establishes Lupin as a leader in sustainable growth. The company made progress across Environmental, Social, and Governance pillars, including increased renewable energy use, reduced carbon emissions, water-positive operations, diversity and inclusion initiatives, community health programs, enhanced transparency, and strengthened corporate governance with board-level ESG oversight.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,757.10 | #1 4,21,587.10 | 40.19 | #1 54,729.00 | 9.71 | #1 10,980 | 2.89 | 71.24 | |
6,511.50 | 1,72,859.90 | 69.56 | 9,712.00 | 18.67 | 2,191 | 35.10 | 49.85 | |
3,831.80 | 1,29,685.50 | 60.73 | 11,539.40 | 6.99 | 1,911 | 30.46 | 70.96 | |
1,532.10 | 1,23,756.00 | 22.77 | 28,409.50 | 7.12 | 5,291 | 3.71 | 48.07 | |
1,246.00 | 1,03,992.90 | #1 18.11 | 33,741.20 | 16.73 | 5,725 | -0.38 | 52.75 | |
944.45 | 95,033.80 | 18.89 | 23,511.00 | 18.55 | 4,615 | 34.60 | 37.46 | |
2,055.30 | #7 93,876.80 | #4 21.59 | #6 22,909.50 | #5 13.74 | #6 3,306 | #1 72.75 | 65.62 | |
2,267.10 | 93,576.50 | 52.74 | 12,744.20 | #1 20.90 | 2,007 | -21.05 | 33.43 | |
1,222.50 | 71,003.00 | 20.93 | 32,345.60 | 9.43 | 3,484 | 3.81 | 73.28 | |
5,722.50 | 68,421.10 | 28.40 | 13,458.30 | 3.70 | 2,216 | 10.98 | 64.53 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
13.74 %
Net Income Growth
70.82 %
Cash Flow Change
-17.77 %
ROE
41.95 %
ROCE
20.69 %
EBITDA Margin (Avg.)
22.54 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 13,138 | 22,625 | 26,607 | 26,305 | 27,949 | 24,984 | 23,610 | 21,821 | 22,956 | 23,997 | 29,205 |
| Fixed Assets | 4,368 | 8,717 | 11,033 | 10,362 | 11,087 | 7,938 | 7,881 | 7,382 | 8,355 | 8,878 | 9,719 |
| Current Assets | 7,832 | 9,887 | 11,953 | 12,210 | 13,854 | 15,413 | 13,986 | 12,458 | 12,451 | 13,448 | 16,799 |
| Capital Work in Progress | 576 | 2,702 | 2,133 | 2,598 | 1,640 | 940 | 1,066 | 1,146 | 1,238 | 773 | 517 |
| Investments | 1,656 | 16 | 2,136 | 262 | 2,296 | 2,374 | 2,455 | 900 | 517 | 1,075 | 1,146 |
| Other Assets | 6,538 | 11,189 | 11,305 | 13,084 | 12,928 | 13,732 | 12,209 | 12,393 | 12,846 | 13,272 | 17,823 |
| Total Liabilities | 13,138 | 22,625 | 26,607 | 26,305 | 27,949 | 24,984 | 23,610 | 21,821 | 22,956 | 23,997 | 29,205 |
| Current Liabilities | 3,729 | 5,061 | 6,121 | 5,096 | 6,130 | 9,225 | 8,436 | 8,498 | 9,265 | 8,502 | 8,961 |
| Non Current Liabilities | 510 | 6,368 | 6,955 | 7,593 | 8,030 | 3,178 | 1,316 | 1,101 | 1,148 | 1,122 | 2,949 |
| Total Equity | 8,898 | 11,196 | 13,532 | 13,617 | 13,789 | 12,581 | 13,858 | 12,222 | 12,543 | 14,374 | 17,294 |
| Reserve & Surplus | 8,784 | 11,073 | 13,407 | 13,487 | 13,652 | 12,446 | 13,712 | 12,062 | 12,374 | 14,199 | 17,112 |
| Share Capital | 90 | 90 | 90 | 90 | 91 | 91 | 91 | 91 | 91 | 91 | 91 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 1,502 | -1,315 | 2,019 | 729 | -872 | 1,685 | -1,303 | 87 | 273 | -248 | 560 |
| Investing Activities | -1,034 | -6,769 | -2,527 | 470 | -3,283 | 1,107 | -1,240 | 1,292 | -1,287 | -1,712 | -4,172 |
| Operating Activities | 2,733 | -382 | 4,114 | 1,751 | 1,666 | 1,469 | 1,822 | 367 | 1,897 | 3,648 | 3,000 |
| Financing Activities | -197 | 5,836 | 433 | -1,492 | 744 | -891 | -1,885 | -1,572 | -337 | -2,184 | 1,732 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
| Promoter | 46.86 % | 46.84 % | 46.83 % | 46.81 % | 46.78 % | 47.10 % | 47.11 % | 47.10 % | 47.08 % | 47.07 % | 47.05 % | 47.04 % | 47.01 % | 46.98 % | 46.96 % | 46.95 % | 46.92 % | 46.90 % | 46.90 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 16.11 % | 18.28 % | 19.32 % | 21.50 % | 22.04 % | 21.46 % | 21.25 % | 20.49 % |
| DIIs | 22.08 % | 21.68 % | 24.38 % | 24.76 % | 26.84 % | 26.82 % | 27.54 % | 29.38 % | 29.21 % | 28.98 % | 29.42 % | 29.73 % | 27.76 % | 26.78 % | 25.09 % | 24.74 % | 25.41 % | 25.56 % | 26.55 % |
| Government | 0.29 % | 0.28 % | 0.28 % | 0.28 % | 0.29 % | 0.29 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % |
| Public / Retail | 10.02 % | 9.91 % | 10.18 % | 9.99 % | 8.53 % | 8.59 % | 8.41 % | 8.06 % | 7.86 % | 7.06 % | 6.24 % | 5.87 % | 5.70 % | 5.65 % | 5.29 % | 5.17 % | 5.10 % | 5.23 % | 5.12 % |
| Others | 20.75 % | 21.29 % | 18.34 % | 18.16 % | 17.57 % | 17.19 % | 16.94 % | 15.45 % | 15.85 % | 16.89 % | 17.27 % | 1.23 % | 1.23 % | 1.26 % | 1.15 % | 1.10 % | 1.10 % | 1.05 % | 0.94 % |
| No of Share Holders | 0 | 2,93,782 | 3,02,292 | 3,61,288 | 3,61,862 | 3,78,547 | 3,82,828 | 3,78,011 | 3,60,677 | 3,22,678 | 2,89,074 | 2,81,542 | 2,80,248 | 2,88,537 | 2,79,280 | 2,81,988 | 2,83,210 | 2,86,604 | 2,80,256 |
Dividend History
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 7.5 | 5 | 5 | 6 | 6.5 | 4 | 4 | 8 | 12 |
| Dividend Yield (%) | 0.00 | 1.02 | 0.68 | 0.85 | 0.59 | 0.87 | 0.61 | 0.25 | 0.39 | 0.58 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 28 Jul 2021 |  Dividend | ₹ 6.50 /share | 27 Jul 2021 | 1,212.25 | 1,111.60 |
| 15 Jul 2022 | Dividend | ₹ 4.00 /share | 14 Jul 2022 | 683.30 | 643.20 |
| 14 Jul 2023 | Dividend | ₹ 4.00 /share | 14 Jul 2023 | 732.25 | 930.75 |
| 16 Jul 2024 | Dividend | ₹ 8.00 /share | 16 Jul 2024 | 1,655.25 | 1,832.10 |
| 02 Aug 2024 |  Annual General Meeting | NA | 02 Aug 2024 | 1,778.90 | 1,953.55 |
| 07 Nov 2024 |  Quarterly Result Announcement | NA | 07 Nov 2024 | 2,151.95 | 2,166.05 |
| 11 Feb 2025 | Quarterly Result Announcement | NA | 11 Feb 2025 | 2,134.25 | 2,169.40 |
| 14 May 2025 | Quarterly Result Announcement | NA | 14 May 2025 | 2,107.70 | 2,063.00 |
| 25 Jul 2025 | Dividend | ₹ 12.00 /share | 25 Jul 2025 | 2,063.00 | 1,943.40 |
| 05 Aug 2025 | Quarterly Result Announcement | NA | 05 Aug 2025 | 1,930.85 | 1,882.20 |
| 11 Aug 2025 | Annual General Meeting | NA | 11 Aug 2025 | 1,894.70 | 1,918.00 |
| 06 Nov 2025 | Quarterly Result Announcement | NA | 06 Nov 2025 | 1,943.35 | 1,997.00 |
Announcements
Announcement under Regulation 30 (LODR)-Press Release / Media Release
1 day ago
1 day agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release2 days ago
2 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release3 days ago
3 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release4 days ago
4 days agoAnnouncement under Regulation 30 (LODR)-Earnings Call Transcript4 days ago
4 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release4 days ago
4 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation6 days ago
6 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release8 days ago
8 days agoAnnouncement under Regulation 30 (LODR)-Newspaper Publication8 days ago
8 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome9 days ago
9 days agoAnnouncement under Regulation 30 (LODR)-Investor Presentation10 days ago
10 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release10 days ago
10 days agoBoard Meeting Outcome for Outcome Of The Board Meeting For Approval Of The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Half Year Ended September 30 2025.10 days ago
10 days agoApproval Of The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Half Year Ended September 30 2025.10 days ago
10 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 05, 2025
Nov 05, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationOct 31, 2025
Oct 31, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseOct 30, 2025
Oct 30, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseOct 28, 2025
Oct 28, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSOct 28, 2025
Oct 28, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 27, 2025
Oct 27, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseOct 24, 2025
Oct 24, 2025Board Meeting Intimation for Considering And Taking On Record The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Half Year Ended September 30 2025.Oct 22, 2025
Oct 22, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseOct 13, 2025
Oct 13, 2025U.S. FDA Has Conducted A Pre-Approval Inspection At The Companys Manufacturing Facility Located In Somerset New Jersey U.S.A.Oct 11, 2025
Oct 11, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSOct 10, 2025
Oct 10, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseOct 09, 2025
Oct 09, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseOct 08, 2025
Oct 08, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 07, 2025
Oct 07, 2025U.S. FDA Has Determined The Inspection Of Companys Pithampur Unit-2 Manufacturing Facility As Official Action Indicated.Oct 04, 2025
Oct 04, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseOct 03, 2025
Oct 03, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseOct 01, 2025
Oct 01, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 30, 2025
Sep 30, 2025Announcement under Regulation 30 (LODR)-Change in ManagementSep 30, 2025
Sep 30, 2025Announcement under Regulation 30 (LODR)-AcquisitionSep 29, 2025
Sep 29, 2025Closure of Trading WindowSep 26, 2025
Sep 26, 2025 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportSep 25, 2025
Sep 25, 2025Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotSep 25, 2025
Sep 25, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 24, 2025
Sep 24, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSSep 23, 2025
Sep 23, 2025U.S. FDA Has Conducted A Product-Specific Pre-Approval Inspection At The CompanyS Pune Biotech Facility.Sep 20, 2025
Sep 20, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 17, 2025
Sep 17, 2025U.S. FDA Has Conducted An Inspection Of CompanyS Injectable Facility At Nagpur.Sep 16, 2025
Sep 16, 2025ESG Rating By ESG Risk Assessments And Insights Limited.Sep 13, 2025
Sep 13, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 11, 2025
Sep 11, 2025U.S. FDA Has Conducted A Product-Specific Pre-Approval Inspection At The CompanyS Chhatrapati Sambhajinagar (Aurangabad) Manufacturing FacilitySep 06, 2025
Sep 06, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 03, 2025
Sep 03, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 03, 2025
Sep 03, 2025ESG Rating By Crisil ESG Ratings & Analytics Ltd.Aug 29, 2025
Aug 29, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 27, 2025
Aug 27, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 27, 2025
Aug 27, 2025Mutual Fund Holdings
SBI Mid Cap Direct Plan-Growth 
Franklin India Flexi Cap Fund Direct-Growth 
Mirae Asset Large & Midcap Fund Direct-Growth 
Sundaram Mid Cap Fund Direct-Growth 
Tata Arbitrage Fund Direct - Growth 
Kotak Arbitrage Fund Direct-Growth 
Aditya Birla Sun Life Mid Cap Direct Fund-Growth 
Bandhan Large & Mid Cap Fund Direct-Growth 
ICICI Prudential Focused Equity Fund Direct-Growth 
HDFC Innovation Fund Direct-Growth 
Union Flexi Cap Fund Direct-Growth 
Axis Midcap Direct Plan-Growth 
UTI Mid Cap Fund Direct-Growth 
JM Midcap Fund Direct - Growth 
Parag Parikh Flexi Cap Fund Direct-Growth Technical Indicators
RSI(14)
Neutral 65.62
ATR(14)
Less Volatile 42.25
STOCH(9,6)
Neutral 76.05
STOCH RSI(14)
Overbought 100.00
MACD(12,26)
Bullish 11.76
ADX(14)
Weak Trend 18.71
UO(9)
Bearish 47.79
ROC(12)
Uptrend And Accelerating 7.12
WillR(14)
Overbought -8.22
About Lupin
Lupin is a global pharmaceutical company producing branded and generic formulations, biotechnology products, and active pharmaceutical ingredients. Founded in 1983, it operates in over 100 markets, specializing in cardiovascular, diabetology, asthma, pediatric, central nervous system, gastrointestinal, anti-infective, and NSAID therapies. Lupin is a leader in anti-TB and cephalosporins segments. The company has expanded through acquisitions and partnerships, entering markets in Japan, Germany, Australia, South Africa, and the Philippines. Lupin has manufacturing facilities in various locations and has received FDA approvals for multiple generic drugs. The company has also launched innovative products and entered strategic alliances with other pharmaceutical companies for drug development and marketing.
Website
Chairperson NameM D Gupta
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
